title: [Use of intravitreal bevacizumab for macular edema in branch retinal vein occlusion].
abstract: OBJECTIVE
  To study the effect of intravitreal bevacizumab on macular edema secondary to branch retinal vein occlusion (BRVO).
  
  
  METHODS
  6 eyes of 5 patients averaging 70 years, who had received either retinal photocoagulation or trans-tenon retrobulbar triamcinolone injections or both, but in whom the macular edema remained. There was an average of 337 days from BRVO onset to injection of bevacizumab. Corrected vision and foveal thickness were measured.
  
  
  RESULTS
  Visual acuity and foveal thickness improved significantly one month after injection.
  
  
  CONCLUSIONS
  Intravitreal injection of bevacizumab is effective for a short time.
authors.affiliation: Eguchi Eye Hospital, Japan. himawari@jim.u-ryukyu.ac.jp
authors.forename: Yukihide
authors.initials: Y
authors.lastname: Yamauchi
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Mori
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Masahara
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kameda
authors.forename: Michiro
authors.initials: M
authors.lastname: Suzuki
authors.forename: Yosai
authors.initials: Y
authors.lastname: Mori
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Eguchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab